18
Total investments
11
Early stage
2
Mid stage
3
Late stage
11y
Years active
Portfolio
18 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Investor
Apr 2025
Aspivix is a medical device company in women’s health, based in Switzerland and in California, developing next-generation devices for gynecology.
Our flagship product, carevix®, is the world’s first suction cervical stabilizer clinically proven to reduce pain and bleeding associated with transcervical procedures commonly performed in gynecology, including IUD insertion, hysteroscopy, cervical biopsies, fertility treatments, and more.
Recognized as one the Best Inventions 2024 by TIME, carevix® is a medical device that has received in 2023 FDA-clearance for the US market, as well as the CE-Mark for the European countries. carevix® study published in the international journal, Contraception, in March 2023 demonstrated superiority over the use of a single tooth tenaculum, reducing the pain by up to 73% and the bleeding by up to 83% in IUD insertions.
More than 120 million women worldwide have procedures using the antiquated single-tooth tenaculum, an instrument invented over a century ago, without consideration of a womans anatomy or pain, and yet it is still considered to be the standard of care in gynecology.
At Aspivix, we think women deserve more. We are driven by our vision to make gynecology modern.
Investor
Mar 2024
Ealyx is a B2B SaaS for e-commerce that allows consumers to pay new purchases with used things.
Our unrivaled, incredibly easy-to-use product aligns Circularity and profitability for businesses while unlocking unprecedented opportunities for financial stakeholders.
We are a technology company based in Barcelona and open to the world, with the vision to make a significant global contribution to the required changes in the current take-make-waste consumption model.
Investor
Dec 2022
Graphext is an advanced analytics solution to help businesses make better decisions based on data. We capture their data, enrich it and provide a powerful visual interface to find actionable insights about their customers, market and products.
Investor
May 2022
Komon is a platform for creators of all kinds to launch NFT-accessed spaces to monetize and engage their communities 💜. The company was launched in early 2022.
Today’s creative industries advertising-based model is broken. On the one hand, creators are trapped in a vicious circle 🌀 where they just create algorithm-friendly content, a job that detaches them from their craft and that is highly under-monetised (even the best paid creators worldwide still make less than a 1$ per supporter per year 😢!). Users, on the other hand, have also been trapped through their attention based on having them constantly consuming content to an unhealthy degree 😣, for the sake of increasing advertising reach.
Komon wants to rewrite the code of monetization and engagement by allowing creators to setup exclusive online spaces ☄️ that are accessible via purchasing an NFT working as an access key and space member card, where supporters can finally feel special, have power/influence, and interact with a curated community.
We just raised a $2M pre-seed round with reputed European and US VCs and angel investors, and we are building a world class team and an amazing product to solve the needs of creative communities 🤸🏾♀️.
Our vision is to provide any creative community with the means to take its pursuit beyond. If you are passionate about how technology can help creators and communities make a better living out of their creativity, we would love to meet you 😻!
Investor
Mar 2022
Visualiza todos tus gastos e ingresos a tiempo real, categorizados, y desde una única plataforma.
Investor
May 2021
GrowPro creamos experiencias únicas de estudio y trabajo en destinos internacionales para almas aventureras.🙌 ¿Nuestros destinos? Australia, Canadá, Nueva Zelanda, Irlanda, Malta y Estados Unidos🌏
🤓Asesoramos a quienes buscan vivir en el extranjero mientras mejoran su educación y abren nuevo horizontes.
😏Apoyamos a los estudiantes antes de su viaje y durante su estancia,
para asegurar que sacan el máximo provecho de su experiencia
en el extranjero, siendo nuestros servicios totalmente gratuitos para ellos.
👐A través de nuestro servicio personalizado y eventos locales (en
origen y en destino), llegamos a miles de personas y estudiantes
que buscan nuestro consejo.
🤙Nos apasiona tener la oportunidad de ayudar a otras personas a vivir la misma experiencia que cada uno de nosotros ha tenido en algún destino extranjero.
Esa es nuestra razón de ser, acompañarte a vivir la mejor aventura de tu vida. ✋🌏
Investor
Apr 2021
Aortyx is a pioneer company focused on developing new medical devices for vascular repair. Our mission is to deliver the best available treatments to our patients with the most advanced available technology.
We spin-off from the IQS School of Engineering and Hospital Clínic de Barcelona.
Investor
Apr 2021
Quantum-Mechanics and Machine Learning Drug Discovery.
Pharmacelera develops proprietary Computer-Aided Drug Design software and provides access to its technology through flexible licensing options and computational chemistry services. The methodology mines an unexploited chemical space, finding starting points with larger chemical diversity and improving the creativity of chemists.
The technology is based on accurate Quantum-Mechanics algorithms, Machine Learning and High-Performance Computing (HPC) and it derives from more than 25 years of research.
Pharmacelera helps companies in Target Identification, Hit-Identification, Hit-to-Lead and Lead Optimization drug discovery stages by finding novel hits, improving ligand binding properties (ADME, Tox, ...), obtaining insights of ligand / receptor interactions and identifying original backup compounds.
Learn more on how to de-risk your drug discovery project by emailing us at contact@pharmacelera.com or by visiting our webpage at www.pharmacelera.com
Investor
Mar 2021
CORIFY Care is a start-up funded by main world-wide experts on cardiac arrhythmias which is going to introduce in the market a novel medical device to non-invasively map cardiac arrhythmias in real time. This novel technology will improve the treatment in more than 10 million of atrial fibrillation patients only in Europe.
Our non-invasive electro-anatomical mapping systems displays the activation patterns in each point of the heart without the need of invasive catheters, allowing the possibility to map all atrial fibrillation patients even during a regular visit to the cardiologist.
CORIFY care was created thanks to the positive resolution of AF-FINE project, funded by EIT Health.
CORIFY Care is located in Madrid, Spain, one of the most attractive places to work/live on the South of Europe.
This channel shares content for physicians located in Europe.
Seed Investor
Jan 2021
Enola es la plataforma de deporte y salud para personas de más de cincuenta años donde vas a encontrar: planes de entrenamiento personalizados, talleres temáticos, consejos deportivos y muchas más actividades para ponerte en forma.
Queremos acompañarte en el camino hacia la mejora de tu calidad de vida. Estaremos cada día al pie del cañón para motivarte y ayudarte a cumplir tus objetivos. En Enola no hay tiempo para rendirse (ni para aburrirse).
📲 Disponible para iOS y Android.
Seed Investor
Dec 2017
Connect with your partners for efficient transactions every time: we have tailored our platform to meet the needs of the players in the fresh produce market.
🥕 Consentio for suppliers: focus on business relationships, leave the admin to us!
Maximize your sales with a data powered tool: work comfortably, progress efficiently and strengthen your business
🛒 Consentio for buyers: real-time access, smarter purchasing!
Stay Ahead, Secure the Best Deals, and build Lasting Partnerships
Investor
Dec 2017
Connect with your partners for efficient transactions every time: we have tailored our platform to meet the needs of the players in the fresh produce market.
🥕 Consentio for suppliers: focus on business relationships, leave the admin to us!
Maximize your sales with a data powered tool: work comfortably, progress efficiently and strengthen your business
🛒 Consentio for buyers: real-time access, smarter purchasing!
Stay Ahead, Secure the Best Deals, and build Lasting Partnerships
Advisor & Seed Investor
Sep 2017
Usizy is the top size recommendation and prediction solution for eCommerce and the latest technology of its kind: combining the most advanced machine learning, big data, and isomorphic algorithms.
uSizy Smart Business is the best platform, designed with and for retailers, offering comprehensive analytics to master sizing and maximize success in stock, logistics and pricing – all possible with only 2 lines of code to integrate.
▶️ uSizy Size Adviser: Recommend the exact size for apparel, footwear and bikes to users. Boost conversion and customer loyalty, reduce returns, increase average cart, decrease the buying decision time and more.
▶️ uSizy Smart Stock: Manage your stock supply more effectively by preventing and improving stock breaks, leveraging demand data and the conversion rate by size for each product.
▶️ uSizy Smart Pricing: Adjust prices by size, product and category to boost margins with predictions based on the conversion rate and demand for each size.
▶️ uSizy Smart Logistics: Plan deliveries, transportation and stock logistics efficiently by anticipating products and sizes with a high probability of return.
▶️ uSizy Worky: The best size assignment tool for uniforms and workwear, used by manufacturers, distributors and companies for their own employees.
uSizy is a partner, not simply a provider. We achieve immediate results along with continuous improvement.
Are you ready to take your business up a size?
Getting started is easy. 2 lines of code and we're a team. Contact us today at hello@usizy.com!
Show all 18 investments ↓
Experience · 26 entries
All (26)
Investments (18)
Founder (3)
2025
Investor
Apr 2025
Aspivix is a medical device company in women’s health, based in Switzerland and in California, developing next-generation devices for gynecology.
Our flagship product, carevix®, is the world’s first suction cervical stabilizer clinically proven to reduce pain and bleeding associated with transcervical procedures commonly performed in gynecology, including IUD insertion, hysteroscopy, cervical biopsies, fertility treatments, and more.
Recognized as one the Best Inventions 2024 by TIME, carevix® is a medical device that has received in 2023 FDA-clearance for the US market, as well as the CE-Mark for the European countries. carevix® study published in the international journal, Contraception, in March 2023 demonstrated superiority over the use of a single tooth tenaculum, reducing the pain by up to 73% and the bleeding by up to 83% in IUD insertions.
More than 120 million women worldwide have procedures using the antiquated single-tooth tenaculum, an instrument invented over a century ago, without consideration of a womans anatomy or pain, and yet it is still considered to be the standard of care in gynecology.
At Aspivix, we think women deserve more. We are driven by our vision to make gynecology modern.
2024
Investor
Mar 2024
Ealyx is a B2B SaaS for e-commerce that allows consumers to pay new purchases with used things.
Our unrivaled, incredibly easy-to-use product aligns Circularity and profitability for businesses while unlocking unprecedented opportunities for financial stakeholders.
We are a technology company based in Barcelona and open to the world, with the vision to make a significant global contribution to the required changes in the current take-make-waste consumption model.
2022
Investor
Dec 2022
Graphext is an advanced analytics solution to help businesses make better decisions based on data. We capture their data, enrich it and provide a powerful visual interface to find actionable insights about their customers, market and products.
Investor
May 2022
Komon is a platform for creators of all kinds to launch NFT-accessed spaces to monetize and engage their communities 💜. The company was launched in early 2022.
Today’s creative industries advertising-based model is broken. On the one hand, creators are trapped in a vicious circle 🌀 where they just create algorithm-friendly content, a job that detaches them from their craft and that is highly under-monetised (even the best paid creators worldwide still make less than a 1$ per supporter per year 😢!). Users, on the other hand, have also been trapped through their attention based on having them constantly consuming content to an unhealthy degree 😣, for the sake of increasing advertising reach.
Komon wants to rewrite the code of monetization and engagement by allowing creators to setup exclusive online spaces ☄️ that are accessible via purchasing an NFT working as an access key and space member card, where supporters can finally feel special, have power/influence, and interact with a curated community.
We just raised a $2M pre-seed round with reputed European and US VCs and angel investors, and we are building a world class team and an amazing product to solve the needs of creative communities 🤸🏾♀️.
Our vision is to provide any creative community with the means to take its pursuit beyond. If you are passionate about how technology can help creators and communities make a better living out of their creativity, we would love to meet you 😻!
Show all 26 entries ↓
Investment activity
2015–2025 · 18 investments
Recent (last 2 years)Earlier
